论文部分内容阅读
本文报告21例 MDS,包括 RAEB、RAEB-t、CMML 及有严重血细胞减少的 RA 和 RAS 患者单独使用粒-巨噬细胞集落刺激因子(GM-CSF)或加用小剂量阿糖胞苷(LD-Ara-C)治疗的结果。除1例于霍奇金病治疗后转化为 RAEB-t 外,均为原发性;有1例已用 LD-Ara-C 6个月外。其余均为初治者。随机分为两组,Ⅰ组11例,单用 GM-CSF;Ⅱ组10例,GM-CSF 加 LD-Ara-C 治疗。GM-CSF 3μg/kg/d,Ara-C 20mg/m~2/d,均皮下注射,用药14天为1
This article reports the results of 21 patients with MDS, including RAEB, RAEB-t, CMML and patients with severe cytopenia of RA and RAS alone using granulocyte-macrophage colony stimulating factor (GM-CSF) or small doses of cytarabine (LD -Ara-C) treatment results. All cases were primary except for 1 case that was converted to RAEB-t after Hodgkin’s disease treatment and 1 case had been treated with LD-Ara-C for 6 months. The rest are naive. Randomly divided into two groups, Ⅰ group of 11 cases, with GM-CSF alone; Ⅱ group of 10 cases, GM-CSF plus LD-Ara-C treatment. GM-CSF 3μg / kg / d, Ara-C 20mg / m ~ 2 / d, were injected subcutaneously, medication for 14 days was 1